Hillstream Biopharma (NASDAQ:CNTN) Downgraded by Wall Street Zen to Sell

Key Points

• Wall Street Zen downgraded Hillstream Biopharma (NASDAQ:CNTN) from a "hold" to a sell, Weiss Ratings initiated coverage with a "sell (e+)", and MarketBeat reports the consensus rating is Sell.
• Shares opened at $3.26, trade in a 12‑month range of $0.95–$9.08, and the company has a market cap of $184.7 million with a negative P/E of -0.82.
• Hillstream is a pre‑clinical biotech focused on ferroptosis/iron‑mediated cell death (IMCD) therapies, with pipeline candidates including HSB‑1216, HSB‑888, HSB‑510, and HSB‑114 targeting treatment‑resistant solid tumors.

Hillstream Biopharma (NASDAQ:CNTN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Separately, Weiss Ratings initiated coverage on Hillstream Biopharma in a research report on Monday, March 9th. They set a "sell (e+)" rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of "Sell".

Hillstream Biopharma Price Performance

NASDAQ CNTN opened at $3.26 on Friday. Hillstream Biopharma has a 12-month low of $0.95 and a 12-month high of $9.08. The stock has a market cap of $184.70 million, a price-to-earnings ratio of -0.82 and a beta of 1.57.

Hillstream Biopharma (NASDAQ:CNTN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.54 earnings per share (EPS) for the quarter.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.